| 0.92 -0 (-0.01%) | 10-08 15:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.12 | 1-year : | 1.19 |
| Resists | First : | 0.96 | Second : | 1.01 |
| Pivot price | 0.94  |
|||
| Supports | First : | 0.88 | Second : | 0.73 |
| MAs | MA(5) : | 0.92  |
MA(20) : | 0.94 |
| MA(100) : | 0.58 |
MA(250) : | 0.75 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.1 |
D(3) : | 32.5 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 1.85 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HOWL ] has closed above bottom band by 33.1%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.93 | 0.93 - 0.94 |
| Low: | 0.9 - 0.9 | 0.9 - 0.91 |
| Close: | 0.91 - 0.92 | 0.92 - 0.93 |
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Mon, 05 Oct 2026
Werewolf Therapeutics (HOWL) Steadies Near $0.93 as Micro-Cap Biotech Presses Against Resistance - Fear Greed Extreme - https://www.dars.gov.et/
Fri, 02 Oct 2026
Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History - Benzinga
Mon, 21 Sep 2026
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
Fri, 21 Aug 2026
Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Fri, 21 Aug 2026
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Yahoo Finance
Fri, 21 Aug 2026
Werewolf Therapeutics stock soars 120% on Ambros merger deal - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 29 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 934 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -164.9 % |
| Operating Margin | 40.6 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -119.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.11 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 2.7 |
| Price to Sales | 2.12 |
| Price to Cash Flow | -1.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|